[{"orgOrder":0,"company":"PRM Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Chlorthalidone","moa":"Thiazide-sensitive sodium-chloride cotransporter","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PRM Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PRM Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PRM Pharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by PRM Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          China Battery Fair
                          Not Confirmed
                          China Battery Fair
                          Not Confirmed

                          Details : HemiClor (12.5 mg chlorthalidone) is a thiazide-like diuretic which is indicated for the treatment of hypertension in adults, to lower blood pressure.

                          Product Name : HemiClor

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 06, 2025

                          Lead Product(s) : Chlorthalidone

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank